{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:07Z","timestamp":1790673907660,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are still controversies about the use of interim positron emission tomography\/computed tomography (PET\/CT) in indolent non-Hodgkin lymphoma due to the variable fluorodeoxyglucose (FDG) avidity. Therefore, this study aimed to evaluate the roles of interim PET\/CT in marginal zone lymphoma (MZL), a representative indolent lymphoma. We analyzed the data of 146 MZL patients. All were treated with rituximab-containing immunochemotherapy. Interim PET\/CT scan was performed after 2\u20133 cycles of therapy, and the response was assessed using the Deauville 5-point scales (5-PS) and a semi-quantitative assessment using the SUVmax reduction rate (\u0394SUVmax). Progression-free survival (PFS) was well stratified according to a visual assessment of interim PET\/CT using 5-PS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Particularly, there was a significant difference in PFS between patients with interim score 1\u20132 and those with score 3. However, \u0394SUVmax did not predict the survival outcome using 59.8% of the optimal cutoff value. In the multivariate analysis, failure to achievement of grade 1\u20132 in interim PET\/CT was significantly associated with inferior PFS (HR, 2.154; 95% CI 1.071\u20134.332; <jats:italic>p<\/jats:italic>\u2009=\u20090.031). The interim PET\/CT response based on the 5-PS is useful for predicting PFS of patients with MZL in the post-rituximab era.<\/jats:p>","DOI":"10.1038\/s41598-020-68310-w","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T10:04:02Z","timestamp":1594807442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic significance of interim PET\/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era"],"prefix":"10.1038","volume":"10","author":[{"given":"Ga-Young","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae sik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Young","family":"Yhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"68310_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington, S. F. & Kluge, R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur. J. Nucl. Med. Mol. Imaging 44, 97\u2013110. https:\/\/doi.org\/10.1007\/s00259-017-3690-8 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"68310_CR2","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 32, 3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800 (2014).","journal-title":"J. Clin. Oncol."},{"key":"68310_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.15838","volume":"185","author":"A Pavlovsky","year":"2019","unstructured":"Pavlovsky, A. et al. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. Br. J. Haematol. 185, 865\u2013873. https:\/\/doi.org\/10.1111\/bjh.15838 (2019).","journal-title":"Br. J. Haematol."},{"key":"68310_CR4","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/jco.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis, J. et al. Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J. Clin. Oncol. 30, 4317\u20134322. https:\/\/doi.org\/10.1200\/jco.2012.43.0934 (2012).","journal-title":"J. Clin. Oncol."},{"key":"68310_CR5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","volume":"106","author":"C Haioun","year":"2005","unstructured":"Haioun, C. et al. [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 106, 1376\u20131381. https:\/\/doi.org\/10.1182\/blood-2005-01-0272 (2005).","journal-title":"Blood"},{"key":"68310_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00277-015-2553-2","volume":"95","author":"HJA Adams","year":"2016","unstructured":"Adams, H. J. A., Nievelstein, R. A. J. & Kwee, T. C. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: A systematic review. Ann. Hematol. 95, 11\u201318. https:\/\/doi.org\/10.1007\/s00277-015-2553-2 (2016).","journal-title":"Ann. Hematol."},{"key":"68310_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12185-018-2403-9","volume":"107","author":"KH Yoo","year":"2018","unstructured":"Yoo, K. H., Lee, H., Suh, C. & On Behalf of the CISL. Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial. Int. J. Hematol. 107, 395\u2013404. https:\/\/doi.org\/10.1007\/s12185-018-2403-9 (2018).","journal-title":"Int. J. Hematol."},{"key":"68310_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3904\/kjim.2010.25.3.227","volume":"25","author":"SY Oh","year":"2010","unstructured":"Oh, S. Y. & Suh, C. Non-gastric marginal zone B-cell lymphoma in Korea: Clinical features, treatment, and prognostic factors. Korean J. Intern. Med. 25, 227\u2013236. https:\/\/doi.org\/10.3904\/kjim.2010.25.3.227 (2010).","journal-title":"Korean J. Intern. Med."},{"key":"68310_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/asheducation-2012.1.426","volume":"2012","author":"PL Zinzani","year":"2012","unstructured":"Zinzani, P. L. The many faces of marginal zone lymphoma. Hematology Am. Soc. Hematol. Educ. Program. 2012, 426\u2013432. https:\/\/doi.org\/10.1182\/asheducation-2012.1.426 (2012).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"68310_CR10","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","volume":"127","author":"C Thieblemont","year":"2016","unstructured":"Thieblemont, C., Molina, T. & Davi, F. Optimizing therapy for nodal marginal zone lymphoma. Blood 127, 2064\u20132071. https:\/\/doi.org\/10.1182\/blood-2015-12-624296 (2016).","journal-title":"Blood"},{"key":"68310_CR11","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","volume":"102","author":"A Conconi","year":"2003","unstructured":"Conconi, A. et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102, 2741\u20132745. https:\/\/doi.org\/10.1182\/blood-2002-11-3496 (2003).","journal-title":"Blood"},{"key":"68310_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-0609.2007.00895.x","volume":"79","author":"C Perry","year":"2007","unstructured":"Perry, C. et al. Diagnostic accuracy of PET\/CT in patients with extranodal marginal zone MALT lymphoma. Eur. J. Haematol. 79, 205\u2013209. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00895.x (2007).","journal-title":"Eur. J. Haematol."},{"key":"68310_CR13","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1080\/10428190600733499","volume":"47","author":"L Alinari","year":"2006","unstructured":"Alinari, L. et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk. Lymphoma 47, 2096\u20132101. https:\/\/doi.org\/10.1080\/10428190600733499 (2006).","journal-title":"Leuk. Lymphoma"},{"key":"68310_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/annonc\/mdi093","volume":"16","author":"KP Beal","year":"2005","unstructured":"Beal, K. P., Yeung, H. W. & Yahalom, J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: A report of 42 cases. Ann. Oncol. 16, 473\u2013480. https:\/\/doi.org\/10.1093\/annonc\/mdi093 (2005).","journal-title":"Ann. Oncol."},{"key":"68310_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000070290","volume":"64","author":"M Hoffmann","year":"2003","unstructured":"Hoffmann, M. et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64, 336\u2013340. https:\/\/doi.org\/10.1159\/000070290 (2003).","journal-title":"Oncology"},{"key":"68310_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.clml.2019.10.006","volume":"20","author":"D Albano","year":"2020","unstructured":"Albano, D., Durmo, R., Treglia, G., Giubbini, R. & Bertagna, F. (18)F-FDG PET\/CT or PET role in MALT lymphoma: An open issue not yet solved-a critical review. Clin. Lymphoma Myeloma Leuk. 20, 137\u2013146. https:\/\/doi.org\/10.1016\/j.clml.2019.10.006 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"68310_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00259-016-3518-y","volume":"44","author":"D Albano","year":"2017","unstructured":"Albano, D. et al. 18F-FDG PET\/CT in gastric MALT lymphoma: a bicentric experience. Eur. J. Nucl. Med. Mol. Imaging 44, 589\u2013597. https:\/\/doi.org\/10.1007\/s00259-016-3518-y (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"68310_CR18","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s00261-018-1542-z","volume":"43","author":"D Albano","year":"2018","unstructured":"Albano, D., Giubbini, R. & Bertagna, F. 18F-FDG PET\/CT in splenic marginal zone lymphoma. Abdom. Radiol. (N.Y.) 43, 2721\u20132727. https:\/\/doi.org\/10.1007\/s00261-018-1542-z (2018).","journal-title":"Abdom. Radiol. (N.Y.)"},{"key":"68310_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hon.2152","volume":"33","author":"G Treglia","year":"2015","unstructured":"Treglia, G. et al. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: A meta-analysis. Hematol. Oncol. 33, 113\u2013124. https:\/\/doi.org\/10.1002\/hon.2152 (2015).","journal-title":"Hematol. Oncol."},{"key":"68310_CR20","unstructured":"20National Comprehensive Cancer Network. B-Cell Lymphomas (Version 4.2019), https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"68310_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/hon.2414","volume":"36","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Complete metabolic response (CMR) in positron emission tomography\u2013computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL). Hematol. Oncol. 36, 56\u201361. https:\/\/doi.org\/10.1002\/hon.2414 (2018).","journal-title":"Hematol. Oncol."},{"key":"68310_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","volume":"130","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont, C. et al. A MALT lymphoma prognostic index. Blood 130, 1409\u20131417. https:\/\/doi.org\/10.1182\/blood-2017-03-771915 (2017).","journal-title":"Blood"},{"key":"68310_CR23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan, M., Gallamini, A., Meignan, M., Gallamini, A. & Haioun, C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk. Lymphoma 50, 1257\u20131260. https:\/\/doi.org\/10.1080\/10428190903040048 (2009).","journal-title":"Leuk. Lymphoma"},{"key":"68310_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1179\/174313208X325191","volume":"31","author":"A Rijbroek","year":"2009","unstructured":"Rijbroek, A., Boellaard, R., Vriens, E. M., Lammertsma, A. A. & Rauwerda, J. A. Comparison of transcranial Doppler ultrasonography and positron emission tomography using a three-dimensional template of the middle cerebral artery. Neurol. Res. 31, 52\u201359. https:\/\/doi.org\/10.1179\/174313208X325191 (2009).","journal-title":"Neurol. Res."},{"key":"68310_CR25","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford, J. et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N. Engl. J. Med. 372, 1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648 (2015).","journal-title":"N. Engl. J. Med."},{"key":"68310_CR26","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/jco.2013.51.9298","volume":"32","author":"JMM Raemaekers","year":"2014","unstructured":"Raemaekers, J. M. M. et al. Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial. J. Clin. Oncol. 32, 1188\u20131194. https:\/\/doi.org\/10.1200\/jco.2013.51.9298 (2014).","journal-title":"J. Clin. Oncol."},{"key":"68310_CR27","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/s0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert, A. et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379, 1791\u20131799. https:\/\/doi.org\/10.1016\/s0140-6736(11)61940-5 (2012).","journal-title":"Lancet"},{"key":"68310_CR28","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2016-05-672196","volume":"129","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill, S. & Casasnovas, R.-O. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: Do we trust the driver?. Blood 129, 3059\u20133070. https:\/\/doi.org\/10.1182\/blood-2016-05-672196 (2017).","journal-title":"Blood"},{"key":"68310_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11899-012-0129-y","volume":"7","author":"R-O Casasnovas","year":"2012","unstructured":"Casasnovas, R.-O. et al. Early interim PET scans in diffuse large B-Cell lymphoma: Can there be consensus about standardized reporting, and can PET scans guide therapy choices?. Curr. Hematol. Malig. Rep. 7, 193\u2013199. https:\/\/doi.org\/10.1007\/s11899-012-0129-y (2012).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"68310_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","volume":"118","author":"R-O Casasnovas","year":"2011","unstructured":"Casasnovas, R.-O. et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118, 37\u201343. https:\/\/doi.org\/10.1182\/blood-2010-12-327767 (2011).","journal-title":"Blood"},{"key":"68310_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hon.2563","volume":"37","author":"D Albano","year":"2019","unstructured":"Albano, D. et al. Prognostic role of baseline (18) F-FDG PET\/CT parameters in MALT lymphoma. Hematol. Oncol. 37, 39\u201346. https:\/\/doi.org\/10.1002\/hon.2563 (2019).","journal-title":"Hematol. Oncol."},{"key":"68310_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.112.110890","volume":"54","author":"A Biggi","year":"2013","unstructured":"Biggi, A. et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J. Nucl. Med. 54, 683\u2013690. https:\/\/doi.org\/10.2967\/jnumed.112.110890 (2013).","journal-title":"J. Nucl. Med."},{"key":"68310_CR33","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","volume":"99","author":"A Gallamini","year":"2014","unstructured":"Gallamini, A. et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99, 1107\u20131113. https:\/\/doi.org\/10.3324\/haematol.2013.103218 (2014).","journal-title":"Haematologica"},{"key":"68310_CR34","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.2967\/jnumed.109.063321","volume":"50","author":"HA Jacene","year":"2009","unstructured":"Jacene, H. A. et al. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med 50, 1760\u20131769. https:\/\/doi.org\/10.2967\/jnumed.109.063321 (2009).","journal-title":"J Nucl Med"},{"key":"68310_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/CCO.0b013e32833d5905","volume":"22","author":"AS Michallet","year":"2010","unstructured":"Michallet, A. S., Trotman, J. & Tychyj-Pinel, C. Role of early PET in the management of diffuse large B-cell lymphoma. Curr Opin Oncol 22, 414\u2013418. https:\/\/doi.org\/10.1097\/CCO.0b013e32833d5905 (2010).","journal-title":"Curr Opin Oncol"},{"key":"68310_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie, M. et al. 18F-FDG avidity in lymphoma readdressed: A study of 766 patients. J. Nucl. Med. 51, 25\u201330. https:\/\/doi.org\/10.2967\/jnumed.109.067892 (2010).","journal-title":"J. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68310-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68310-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68310-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:56:57Z","timestamp":1670335017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68310-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["68310"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-68310-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"11 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11649"}}